Enteral drug absorption in patients with short small bowel: A review

Clinical Pharmacokinetics

Volumn 43, Issue 14, 2004, Pages 951-962

  Severijnen, René ^a   Bayat, Nazila ^a   Bakker, Hans ^a   Tolboom, Jules ^a   Bongaerts, Ger ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CIMETIDINE; CYCLOSPORIN; DICLOFENAC; DIGOXIN; FLUCONAZOLE; HYDROCHLOROTHIAZIDE; INDOMETACIN; ISOSORBIDE DINITRATE; LEVOTHYROXINE; LOPERAMIDE; MESALAZINE; METOCLOPRAMIDE; METOPROLOL; METRONIDAZOLE; MORPHINE; NIFEDIPINE; OCTREOTIDE; OMEPRAZOLE; OPIATE; ORAL CONTRACEPTIVE AGENT; OXPRENOLOL; PARACETAMOL; PINDOLOL; PROCAINAMIDE; PROPANTHELINE BROMIDE; SOTALOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

ANGINA PECTORIS; BILE ACID METABOLISM; CHRONIC DIARRHEA; CROHN DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG FORMULATION; DRUG MEGADOSE; DRUG MONITORING; DRUG SOLUBILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTESTINE ABSORPTION; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE TRANSIT TIME; LACTOBACILLUS; MAJOR DEPRESSION; MALABSORPTION; METABOLIC REGULATION; PRIORITY JOURNAL; REVIEW; SHORT BOWEL SYNDROME; SMALL INTESTINE RESECTION; SODIUM ABSORPTION; STOMACH SECRETION; ULCERATIVE COLITIS; WATER ABSORPTION;

ACETAMINOPHEN; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CARDIOVASCULAR AGENTS; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL ABSORPTION; PHARMACOKINETICS; SHORT BOWEL SYNDROME;

EID: 10044229258     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443140-00001     Document Type: Review

References (89)

1. American Gastroenterological Association. Medical position statement: short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124: 1105-10
2. Touloukian RJ, Walker Smith GJ. Normal intestinal length in preterm infants. J Pediatr Surg 1983; 18: 720-3
3. Goulet O, Ruemmle F, Lacaille F, et al. Irreversible intestinal failure. J Pediatr Gastroenterol Nutr 2004; 38: 250-69
4. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetic and therapeutic applications. Clin Pharmacokinet 2002; 41: 661-80
5. Benet LZ, Kroetz DL, Sheiner LB. The dynamics of drug absorption, distribution and elimination. In: Gilman AG, Goodman LS, Gilman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 3-27
6. DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 2001; 39: 209-28
7. Sjöqvist F, Borga O, Dahl ML, et al. Fundamentals of clinical pharmacology. In: Speight TM, Holford NHG, editors. Avery's drug treatment: a guide to the properties, choice, therapeutic use and economic value of drugs in disease management. Auckland: Adis International, 1997: 15-20
8. Kennedy JM, Riji M. Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet 1998; 35: 293-312
9. Gubbins PO, Bench KE. Drug absorption in gastrointestinal disease and surgery. Pharmacotherapy 1989; 9: 285-95
10. Seidner DL, Matarese LE. Short bowel syndrome: etiology, pathophysiology and management. The Cleveland Clinic Centre for Continuing Education 2003 [online]. Available from URL: http://www.clevelandclinicmeded.com/ selected_topics/shortbowel/introl.asp [Accessed 2004 Sep 30]
11. Weaver LT, Austin S, Cole JT. Small intestinal length: a factor essential for gut adaptation. Gut 1991; 32: 1321-3
12. Höllwarth ME. Short bowel syndrome: pathophysiological and clinical aspects. Pathophysiology 1999; 6: 1-19
13. Vanderhoof JA, Young RJ. Enteral and parenteral nutrition in the care of patients with short-bowel syndrome. Best Pract Res Clin Gastroenterol 2003; 17: 997-1015
14. Bongaerts GPA, Severijnen RSVM, Tangerman A, et al. Bile acid deconjugation by lactobacilli and its effects in patients with a short small bowel. J Gastroenterol 2000; 35: 801-4
15. 2 produced by lactobacilli as cause of abdominal complaints in short small bowel syndrome. In: Severijnen RSVM. Short small bowel in children: complications and treatment strategies [online]. Available from URL: http://webdoc.ubn.kun.nl/mono/s/ severijnen_r/shorsmboi.pdf [Accessed 2004 Sep 30]: 65-73
16. Warner BW, Vanderhoof JA, Reyes JD. What's new in the management of short gut syndrome in children. J Am Coll Surg 2000; 190 (6): 725-36
17. Debru E, Martin GR, Sigalet DL. In vivo measurement of intestinal absorption using 3-0 methylglucose in short bowel syndrome. J Paediatr Surg 2001; 36: 745-9
18. Shike M. The short bowel syndrome. In: Winawer SJ, editor. Management of gastrointestinal disease. New York: Gower Medical Publishing, 1992: 160-2
19. Jeejeebhoy KN. Nutritional aspects of inflammatory bowel disease. In: Kirsner JB, Shorter RG, editor. Inflammatory bowel disease. Baltimore (MD): Williams & Wilkins, 1995: 734-49
20. Kvietys PR. Intestinal physiology relevant to short-bowel syndrome. Eur J Pediatr Surg 1999; 9: 196-9
21. Mehta MU, Venkataramanan R, Burckart GJ. Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 1988; 25: 579-84
22. Muller EA, Kallay Z, Kovarik JM. Bile independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients. Transplantation 1995; 60: 515-7
23. Nyhlin H, Merrick MV, Eastwood MA. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut 1994; 35: 90-3
24. Jacobsen O, Hojgaard L, Moller HE, et al. Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study. BMJ 1985; 290: 1315-8
25. Wesser E. Nutritional aspects of malabsorption. Am J Med 1979; 67: 1014-20
26. Russo Jr J, Watson WA, Nelson EW, et al. Cimetidine bioavailability after massive small bowel resection. Clin Pharm 1982; 1: 558-61
27. Aly A, Barany F, Kollberg B, et al. Effect of an H2-receptor blocking agent on diarrhoea after extensive small bowel resection in Crohn's disease. Acta Med Scand 1980; 207: 119-22
28. Piper DW, de Carle DJ, Talley NJ, et al. Gastrointestinal and hepatic diseases. In: Speight TM, Holford NHG, editors. Avery's drug treatment: a guide to the properties, choice, therapeutic use and economic value of drugs in disease management. Auckland: Adis International, 1997: 934-1021
29. Nightingale JMD, Walker ER, Farthing MJG, et al. Effect of omeprazole on intestinal output in the short bowel syndrome. Aliment Pharmacol Ther 1991; 5: 405-12
30. McLeod RS, Cohen Z, Van BJ, et al. The release profile of a controlled release preparation of 5-aminosalicyclic acid (Rowasa I) in humans. Dis Colon Rectum 1990; 33: 21-5
31. Altman DF. Drugs used in gastrointestinal diseases. In: Katzun BG, editor. Basic and clinical pharmacology. Englewood Cliffs (NJ): Prentice-Hall International, Inc., 1992: 895-6
32. Frieri G, Pimpo MT, Palumbo G, et al. Anastomotic configuration and mucosal 5-aminosalicylic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Am J Gastroenterol 2000; 95: 1486-90
33. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, et al., editors. Goodman and Gilman's the pharmacological basic of therapeutics. New York: McGraw Hill, 1990: 507-8
34. Cann PA, Read NW, Holdsworth CD. Loperamide improves dyspeptic symptoms and accelerates gastric emptying in patients with irritable bowel syndrome [abstract]. Gut 1982; 23: A437
35. Awouters F, Megens A, Verlinden M, et al. Loperamide: survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 1993; 38: 977-95
36. Remington M, Fleming CR, Malagelada JR. Inhibition of postprandial pancreatic and biliary secretion by loperamide in patients with short bowel syndrome. Gut 1982; 23: 98-102
37. Remington M, Malagelada JR, Zinsmeister A, et al. Abnormalities in gastrointestinal motor activity in patients with short bowels: effect of a synthetic opiate. Gasteroenterology 1983; 85: 629-36
38. Galambos JT, Hersh T, Schroder S, et al. Loperamide: a new antidiarrheal agent in the treatment of chronic diarrhea. Gasteroenterology 1976; 70: 1026-9
39. Lennard-Jones JE. Review article: practical management of the short bowel. Aliment Pharmacol Ther 1994; 8: 563-77
40. Lentze MJ. Intestinal adaptation in short-bowel syndrome. Eur J Pediatr 1989; 148: 294-9
41. Nightingale JMD. Management of patients with a short bowel. Nutrition 1999; 15: 633-7
42. Schiller LR. Review article: anti-diarrhoeal pharmacology and therapeutics. Aliment Pharmacol Ther 1995; 9: 87-106
43. Fried M. Octreoide in the treatment of refractory diarrhoea. Digestion 1999; 60 Suppl. 2: 42-6
44. Felser J, Hui KK. Procainamide absorption in short bowel syndrome. J Parenter Enteral Nutr 1983; 9: 154-5
45. Hanyok JJ. Clinical pharmacokinetics of sotalol. Am J Cardiol 1993; 72: 19-26A
46. Silomon M, Bach F, Juckenhofel S, et al. Bioavailability of sotalol in short bowel syndrome. Med Klin 1999; 94: 638-41
47. Vetticaden SJ, Lehman ME, Barnhart GR, et al. Digoxin absorption in a patient with short-bowel syndrome. Clin Pharm 1986; 5: 62-4
48. Gereon CD, Lowe EH, Lindenbaum J. Bioavailability of digoxin tablets in patients with gastrointestinal dysfunction. Am J Med 1980; 69: 43-9
49. Kumer KP, Nwangwu JT, Nwangwu PU. Perspectives on digoxin absorption from small bowel resections. Drug Intel Clin Pharm 1983; 7: 121-3
50. Hall WH, Doherty JE, Gammill J, et al. Tritiated digoxin. XXII: absorption and excretion in malabsorption syndrome. Am J Med 1974; 56: 437-42
51. Jusko WJ, Conti DR, Molson A, et al. Digoxin absorption from tablet elixir. JAMA 1974; 230: 1554-5
52. Ehrenpreis ED, Guerriero S, Nogueras JJ, et al. Malabsorption of digoxin tablets, gel caps and elixir in a patient with an end jejunostomy. Ann Pharmacother 1994; 28: 1239-40
53. Evard D, Aubry JP, Le Quintrec Y, et al. Study of the bioavailability of pindolol in malabsorption syndromes. Br J Clin Pharmacol 1984; 18: 632-7
54. McNeil JJ, Krum H. Cardiovascular diseases. In: Speight TM, Holford HG, editors. Avery's drug treatment: a guide to the properties, choice, therapeutic use and economic value of drugs in disease management. Auckland: Adis International, 1997: 809-96
55. Beerman B, Groschinsky-Grind M, Rosen A. Absorption, metabolism and excretion of C-hydrochlorothiazid. Clin Pharmacol Ther 1976; 19: 531-7
56. Backman L, Beerman B, Groschinsky-Grind M, et al. Malabsorption of hydrochlorothiazide following intestinal shunt surgery. Clin Pharmacokinet 1979; 4: 63-8
57. Mitchell JF, Maas LC, Barger RC. Successful oral anticoagulant therapy in a patient with short bowel syndrome. Am J Hosp Pharm 1977; 34: 171-2
58. Kearns PJ, O'Reily RA. Bioavailability of warfarin in a patient with severe short bowel syndrome. J Parenter Enteral Nutr 1986; 10: 100-1
59. Neuvonen PJ, Kivistö KT. Enhancement of drug absorption by antacids: an unrecognised drug interaction. Clin Pharmacokinet 1994; 27: 120-8
60. Brophy DF, Ford SL, Crouch MA. Warfarin resistance in a patient with short bowel syndrome. Pharmacotherapy 1998; 18: 646-9
61. Majerus PW, Broze Jr JB, Miletich JP, et al. Anticoagulant, thrombolytic and antiplatelet drugs. In: Gilman AG, Rall TW, Nies AS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: McGraw Hill, 1990: 1311-31
62. Lehman ME, Kolb KW, Barnhart GR, et al. Warfarin absorption in a patient with short-bowel syndrome. Clin Pharm 1985; 4: 325-6
63. Lutomski DM, LaFrance RJ, Bower RH, et al. Warfarin absorption after massive small bowel resection. Am J Gastroenterol 1985; 80: 99-102
64. Robbins B, Reiss RA. Amitriptyline absorption in a patient with short bowel syndrome. Am J Gastroenterol 1999; 94: 2302-4
65. Broyles JE, Brown RO, Self TH, et al. Noitriptiline absorption in short bowel syndrome. J Parenter Enteral Nutr 1990; 14: 326-7
66. Heading RC, Nimmo J, Prescott LF, et al. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973; 47: 415-21
67. Holt S, Heading RC, Clements JA, et al. Acetaminophen absorption and metabolism in celiac disease and Crohn's disease. Clin Pharmacol Ther 1981; 30: 232-8
68. Ueno T, Tanaka A, Hamanaka Y, et al. Serum drug concentrations after oral administration of paracetamol to patients with surgical resection of the gastrointestinal tract. Br J Clin Pharmacol 1995; 39: 330-2
69. Nelson EB, Abernethy DR, Greenblatt DJ, et al. Paracetamol absorption from a feeding jejunostomy. Br J Clin Pharmacol 1986; 22: 111-3
70. Nimmo WS, Prescott LF. The influence of posture on paracetamol absorption. Br J Clin Pharmacol 1978; 5: 291-334
71. Stocker ME, Montgomery JE. Serum paracetamol concentrations in adult volunteers following rectal administration. Br J Anaesth 2001; 87: 638-40
72. Hanker JP. Gastrointestinal disease and oral contraception. Am J Obstet Gynecol 1990; 163: 2204-7
73. Stone E, Leiter LA, Lambert JR, et al. L-Thyroxine absorption in patients with short bowel. Clin Endocrinol Metab 1984; 59: 139-41
74. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977; 26: 1-8
75. Brenner GM. Antineoplastic and immunomodulating drugs. In: Brenner GM, editor. Pharmacology. Philadelphia (PA): WB Saunders Co., 2000: 488
76. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107-32
77. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 1996; 136: 117-39
78. Gubbins PO, Bertch KE. Drug absorption in gastrointestinal disease and surgery, clinical pharmacokinetics and therapeutic implications. Clin Pharmacokinet 1991; 21: 431-47
79. Roberts R, Sketris IS, Abraham I, et al. Cyclosporine absorption in two patients with short-bowel syndrome. Drug Intell Clin Pharm 1988; 22: 570-2
80. Mandell GL, Sande MA. Antimicrobial agents, penicillins, cephalosporins and other β-lactam antibiotics. In: Gilman AG, Rall TW, Nies AS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: McGraw Hill, 1990: 1065-97
81. Nahata MC, Freimer N, Hilty MD. Decreased absorption of cefaclor in short bowel syndrome. Drug Intell Clin Pharm 1983; 17: 201-2
82. Thielman NM, Neu HC. Bacterial cell wall inhibitors. In: Brody TM, Larner J, Minneman KP, editors. Human pharmacology. St Louis (MO): Mosby-Year Book Inc., 1998: 655-82
83. Menardi G, Guggenbichler JP. Bioavailability of oral antibiotics in children with short-bowel syndrome. J Pediatr Surg 1984; 19: 84-6
84. Thielman NM, Neu HC. Antimicrobacterial agents. In: Brody TM, Lerner J, Minneman KP, editor. Human pharmacology. St Louis (MO): Mosby-Year Book Inc., 1998: 723-33
85. Joe LA, Jacobs RA, Guglielmo BJ. Systemic absorption of oral fluconazole after gastrointestinal resection [letter]. J Antimicrob Chemother 1994; 33: 1070
86. Iacono G, Carroccio A, Montalto G, et al. Extreme short bowel syndrome: a case for reviewing the guidelines for predicting survival. J Pediatr Gastroenterol Nutr 1993; 16: 216-9
87. Parsons RL. Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes. Clin Pharmacokinet 1977; 2: 45-60
88. Dressman JB, Bass P, Ritschel WA, et al. Gastrointestinal parameters that influence oral medications. J Pharm Sci 1993; 82: 857-72
89. Kanamori Y, Hashizume K, Sugiyama M, et al. Combination therapy with Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides dramatically improved the intestinal function in a girl with short bowel syndrome: a novel synbiotics therapy for intestinal failure. Dig Dis Sci 2001; 46: 2010-6